CD274 and neoplasm: Such an ongoing alteration in the TME and its cross-talk with the tumor compartment suggest that a single biomarker-based (e.g., PD-L1 expression status or TMB status) strategy cannot select patient who should receive or not receive immune checkpoint inhibitor.